A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3)
Principal Investigator
Raewyn BroadyOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
ClinicalTrials.gov#
NCT03112603Status
RecruitingStudy Start/End
Jan 12, 2018 to Jul 30, 2020Locations
Vancouver General HospitalName/Title
Larissa Pals, Research AssistantPhone
604-875-4111 ext.22967Email Address
larissa.pals@bccancer.bc.caPurpose of Study
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.